 |
Jason Cyster, Ph.D., University of California, San Francisco
Dr. Cyster is a Professor in the Department of Microbiology and Immunology and an Investigator with the Howard Hughes Medical Institute at UCSF. His primary research interests are focused on defining molecular cues that guide leukocyte migration into secondary lymphoid organs. He is also examining self-tolerance mechanisms promoting autoreactive B cell elimination within lymphoid organs. |
 |
Roger M. Freidinger, Ph.D., Medicinal Chemistry Consultant
Dr. Freidinger retired from Merck Research Laboratories in 2005 after a 30 year career. He was most recently Executive Director, Medicinal Chemistry. His research activities have focused on the chemistry and medicinal chemistry of peptides, peptidomimetics, small molecule ligands for receptors, and enzyme inhibitors encompassing several therapeutic areas. Honors have included the Vincent du Vigneaud Award, Fellow of the American Association for the Advancement of Science, and the American Chemical Society Ralph Hirschmann Award in Peptide Chemistry. Dr. Freidinger was President of the American Peptide Society from 2003 - 2005. He was a member of the NIH Bio-organic and Natural Products Chemistry Study Section and several other advisory boards. |
 |
Roland Gerritsen van der Hoop, M.D., Ph.D.
Dr. Gerritsen van der Hoop received his degrees at the University of Utrecht in the Netherlands. His career in the pharmaceutical industry started in 1988 with Solvay. Between 1988 and 2002 he held a number of different positions for this company first in Weesp, the Netherlands, and since 1995 in Marietta, GA, including those of Senior Vice-President of R&D and Chief Medical Officer. Prior to joining ENDO Pharmaceuticals in 2003, Dr. Gerritsen van der Hoop was Vice-President of Global Research and Development and Chief Scientific Officer at Serologicals Corporation. He most recently served as Senior Vice-President for Research, Development and Regulatory Affairs at ENDO, during which time Endo obtained market authorization for two new opioid therapeutics, Opana© and Opana ER©. |
 |
Michael Hanley, Ph.D., Amylin Pharmaceuticals, Chair of the Scientific Advisory Board
Dr. Hanley is the Vice President of Discovery Research at Amylin Pharmaceuticals. He was a Senior Consultant for Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron Corporation. Prior to that he held faculty positions at the Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis. Dr. Hanley has served on advisory or review panels for the NIH, the Medical Research Council and Wellcome Trust of Great Britain, and for the governments of Australia, Singapore, New Zealand, Hong Kong, Denmark and Japan. He has set-up and directed research programs in several privately-held biotechnology companies, including Chemocentryx, PsychoGenics, and most recently Harvard-based Resolvyx Pharmaceuticals. |
 |
David Scheinberg, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center
Dr. Scheinberg is the Chairman of the Program in Molecular Pharmacology and Chemistry at the Memorial Sloan-Kettering Cancer Center in New York City. His research program is developing novel, targeted immunotherapies which attempt to exploit effectors and suppressors in the immune system. He is a thought leader in the area of hematological malignancies and radio-immunotherapy and was Chief of Memorial's Leukemia Service between 1992 and 2003. |
|
Nicolas A. F. Chronos, M. D., Saint Joseph's Research Institute
Nicolas Chronos, M.D. is the Chief Medical and Scientific Officer of the American Cardiovascular Research Institute (ACRI) and the Saint Joseph's Research Institute in Atlanta. Dr. Chronos currently oversees approximately 60 preclinical trials at ACRI and 30 clinical trials at the Saint Joseph's Research Institute. Dr. Chronos is a practicing interventional cardiologist and is an Adjunct Professor of Cardiology and Medicine at Duke University.
|
 |
 |
|
 |
|
|
|
